Analysis of baseline parameters in the HALT polycystic kidney disease trials

Vicente Torres, Arlene B. Chapman, Ronald D. Perrone, K. Ty Bae, Kaleab Z. Abebe, James E. Bost, Dana C. Miskulin, Theodore I. Steinman, William E. Braun, Franz T. Winklhofer, Marie C Hogan, Frederic R. Oskoui, Cass Kelleher, Amirali Masoumi, James Glockner, Neil J. Halin, Diego R. Martin, Erick Remer, Nayana Patel, Ivan Pedrosa & 5 others Louis H. Wetzel, Paul A. Thompson, J. Philip Miller, Catherine M. Meyers, Robert W. Schrier

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

HALT PKD consists of two ongoing randomized trials with the largest cohort of systematically studied patients with autosomal dominant polycystic kidney disease to date. Study A will compare combined treatment with an angiotensin-converting inhibitor and receptor blocker to inhibitor alone and standard compared with low blood pressure targets in 558 early-stage disease patients with an eGFR over 60 ml/min per 1.73 m 2. Study B will compare inhibitor-blocker treatment to the inhibitor alone in 486 late-stage patients with eGFR 25-60 ml/min per 1.73 m 2. We used correlation and multiple regression cross-sectional analyses to determine associations of baseline parameters with total kidney, liver, or liver cyst volumes measured by MRI in Study A and eGFR in both studies. Lower eGFR and higher natural log-transformed urine albumin excretion were independently associated with a larger natural log-transformed total kidney volume adjusted for height (ln(HtTKV)). Higher body surface area was independently associated with a higher ln(HtTKV) and lower eGFR. Men had larger height-adjusted total kidney volume and smaller liver cyst volumes than women. A weak correlation was found between the ln(HtTKV) and natural log-transformed total liver volume adjusted for height or natural log liver cyst volume in women only. Women had higher urine aldosterone excretion and lower plasma potassium. Thus, our analysis (1) confirms a strong association between renal volume and functional parameters, (2) shows that gender and other factors differentially affect the development of polycystic disease in the kidney and liver, and (3) suggests an association between anthropomorphic measures reflecting prenatal and/or postnatal growth and disease severity.

Original languageEnglish (US)
Pages (from-to)577-585
Number of pages9
JournalKidney International
Volume81
Issue number6
DOIs
StatePublished - Mar 2 2012

Fingerprint

Polycystic Kidney Diseases
Liver
Kidney
Cysts
Urine
Autosomal Dominant Polycystic Kidney
Body Surface Area
Angiotensins
Aldosterone
Hypotension
Albumins
Potassium
Cross-Sectional Studies
Therapeutics
Growth

Keywords

  • ADPKD
  • chronic renal disease
  • kidney volume
  • polycystic kidney disease
  • renal function

ASJC Scopus subject areas

  • Nephrology

Cite this

Torres, V., Chapman, A. B., Perrone, R. D., Bae, K. T., Abebe, K. Z., Bost, J. E., ... Schrier, R. W. (2012). Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney International, 81(6), 577-585. https://doi.org/10.1038/ki.2011.411

Analysis of baseline parameters in the HALT polycystic kidney disease trials. / Torres, Vicente; Chapman, Arlene B.; Perrone, Ronald D.; Bae, K. Ty; Abebe, Kaleab Z.; Bost, James E.; Miskulin, Dana C.; Steinman, Theodore I.; Braun, William E.; Winklhofer, Franz T.; Hogan, Marie C; Oskoui, Frederic R.; Kelleher, Cass; Masoumi, Amirali; Glockner, James; Halin, Neil J.; Martin, Diego R.; Remer, Erick; Patel, Nayana; Pedrosa, Ivan; Wetzel, Louis H.; Thompson, Paul A.; Miller, J. Philip; Meyers, Catherine M.; Schrier, Robert W.

In: Kidney International, Vol. 81, No. 6, 02.03.2012, p. 577-585.

Research output: Contribution to journalArticle

Torres, V, Chapman, AB, Perrone, RD, Bae, KT, Abebe, KZ, Bost, JE, Miskulin, DC, Steinman, TI, Braun, WE, Winklhofer, FT, Hogan, MC, Oskoui, FR, Kelleher, C, Masoumi, A, Glockner, J, Halin, NJ, Martin, DR, Remer, E, Patel, N, Pedrosa, I, Wetzel, LH, Thompson, PA, Miller, JP, Meyers, CM & Schrier, RW 2012, 'Analysis of baseline parameters in the HALT polycystic kidney disease trials', Kidney International, vol. 81, no. 6, pp. 577-585. https://doi.org/10.1038/ki.2011.411
Torres, Vicente ; Chapman, Arlene B. ; Perrone, Ronald D. ; Bae, K. Ty ; Abebe, Kaleab Z. ; Bost, James E. ; Miskulin, Dana C. ; Steinman, Theodore I. ; Braun, William E. ; Winklhofer, Franz T. ; Hogan, Marie C ; Oskoui, Frederic R. ; Kelleher, Cass ; Masoumi, Amirali ; Glockner, James ; Halin, Neil J. ; Martin, Diego R. ; Remer, Erick ; Patel, Nayana ; Pedrosa, Ivan ; Wetzel, Louis H. ; Thompson, Paul A. ; Miller, J. Philip ; Meyers, Catherine M. ; Schrier, Robert W. / Analysis of baseline parameters in the HALT polycystic kidney disease trials. In: Kidney International. 2012 ; Vol. 81, No. 6. pp. 577-585.
@article{16cfc83137894ba8a7cd424e01e707f8,
title = "Analysis of baseline parameters in the HALT polycystic kidney disease trials",
abstract = "HALT PKD consists of two ongoing randomized trials with the largest cohort of systematically studied patients with autosomal dominant polycystic kidney disease to date. Study A will compare combined treatment with an angiotensin-converting inhibitor and receptor blocker to inhibitor alone and standard compared with low blood pressure targets in 558 early-stage disease patients with an eGFR over 60 ml/min per 1.73 m 2. Study B will compare inhibitor-blocker treatment to the inhibitor alone in 486 late-stage patients with eGFR 25-60 ml/min per 1.73 m 2. We used correlation and multiple regression cross-sectional analyses to determine associations of baseline parameters with total kidney, liver, or liver cyst volumes measured by MRI in Study A and eGFR in both studies. Lower eGFR and higher natural log-transformed urine albumin excretion were independently associated with a larger natural log-transformed total kidney volume adjusted for height (ln(HtTKV)). Higher body surface area was independently associated with a higher ln(HtTKV) and lower eGFR. Men had larger height-adjusted total kidney volume and smaller liver cyst volumes than women. A weak correlation was found between the ln(HtTKV) and natural log-transformed total liver volume adjusted for height or natural log liver cyst volume in women only. Women had higher urine aldosterone excretion and lower plasma potassium. Thus, our analysis (1) confirms a strong association between renal volume and functional parameters, (2) shows that gender and other factors differentially affect the development of polycystic disease in the kidney and liver, and (3) suggests an association between anthropomorphic measures reflecting prenatal and/or postnatal growth and disease severity.",
keywords = "ADPKD, chronic renal disease, kidney volume, polycystic kidney disease, renal function",
author = "Vicente Torres and Chapman, {Arlene B.} and Perrone, {Ronald D.} and Bae, {K. Ty} and Abebe, {Kaleab Z.} and Bost, {James E.} and Miskulin, {Dana C.} and Steinman, {Theodore I.} and Braun, {William E.} and Winklhofer, {Franz T.} and Hogan, {Marie C} and Oskoui, {Frederic R.} and Cass Kelleher and Amirali Masoumi and James Glockner and Halin, {Neil J.} and Martin, {Diego R.} and Erick Remer and Nayana Patel and Ivan Pedrosa and Wetzel, {Louis H.} and Thompson, {Paul A.} and Miller, {J. Philip} and Meyers, {Catherine M.} and Schrier, {Robert W.}",
year = "2012",
month = "3",
day = "2",
doi = "10.1038/ki.2011.411",
language = "English (US)",
volume = "81",
pages = "577--585",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Analysis of baseline parameters in the HALT polycystic kidney disease trials

AU - Torres, Vicente

AU - Chapman, Arlene B.

AU - Perrone, Ronald D.

AU - Bae, K. Ty

AU - Abebe, Kaleab Z.

AU - Bost, James E.

AU - Miskulin, Dana C.

AU - Steinman, Theodore I.

AU - Braun, William E.

AU - Winklhofer, Franz T.

AU - Hogan, Marie C

AU - Oskoui, Frederic R.

AU - Kelleher, Cass

AU - Masoumi, Amirali

AU - Glockner, James

AU - Halin, Neil J.

AU - Martin, Diego R.

AU - Remer, Erick

AU - Patel, Nayana

AU - Pedrosa, Ivan

AU - Wetzel, Louis H.

AU - Thompson, Paul A.

AU - Miller, J. Philip

AU - Meyers, Catherine M.

AU - Schrier, Robert W.

PY - 2012/3/2

Y1 - 2012/3/2

N2 - HALT PKD consists of two ongoing randomized trials with the largest cohort of systematically studied patients with autosomal dominant polycystic kidney disease to date. Study A will compare combined treatment with an angiotensin-converting inhibitor and receptor blocker to inhibitor alone and standard compared with low blood pressure targets in 558 early-stage disease patients with an eGFR over 60 ml/min per 1.73 m 2. Study B will compare inhibitor-blocker treatment to the inhibitor alone in 486 late-stage patients with eGFR 25-60 ml/min per 1.73 m 2. We used correlation and multiple regression cross-sectional analyses to determine associations of baseline parameters with total kidney, liver, or liver cyst volumes measured by MRI in Study A and eGFR in both studies. Lower eGFR and higher natural log-transformed urine albumin excretion were independently associated with a larger natural log-transformed total kidney volume adjusted for height (ln(HtTKV)). Higher body surface area was independently associated with a higher ln(HtTKV) and lower eGFR. Men had larger height-adjusted total kidney volume and smaller liver cyst volumes than women. A weak correlation was found between the ln(HtTKV) and natural log-transformed total liver volume adjusted for height or natural log liver cyst volume in women only. Women had higher urine aldosterone excretion and lower plasma potassium. Thus, our analysis (1) confirms a strong association between renal volume and functional parameters, (2) shows that gender and other factors differentially affect the development of polycystic disease in the kidney and liver, and (3) suggests an association between anthropomorphic measures reflecting prenatal and/or postnatal growth and disease severity.

AB - HALT PKD consists of two ongoing randomized trials with the largest cohort of systematically studied patients with autosomal dominant polycystic kidney disease to date. Study A will compare combined treatment with an angiotensin-converting inhibitor and receptor blocker to inhibitor alone and standard compared with low blood pressure targets in 558 early-stage disease patients with an eGFR over 60 ml/min per 1.73 m 2. Study B will compare inhibitor-blocker treatment to the inhibitor alone in 486 late-stage patients with eGFR 25-60 ml/min per 1.73 m 2. We used correlation and multiple regression cross-sectional analyses to determine associations of baseline parameters with total kidney, liver, or liver cyst volumes measured by MRI in Study A and eGFR in both studies. Lower eGFR and higher natural log-transformed urine albumin excretion were independently associated with a larger natural log-transformed total kidney volume adjusted for height (ln(HtTKV)). Higher body surface area was independently associated with a higher ln(HtTKV) and lower eGFR. Men had larger height-adjusted total kidney volume and smaller liver cyst volumes than women. A weak correlation was found between the ln(HtTKV) and natural log-transformed total liver volume adjusted for height or natural log liver cyst volume in women only. Women had higher urine aldosterone excretion and lower plasma potassium. Thus, our analysis (1) confirms a strong association between renal volume and functional parameters, (2) shows that gender and other factors differentially affect the development of polycystic disease in the kidney and liver, and (3) suggests an association between anthropomorphic measures reflecting prenatal and/or postnatal growth and disease severity.

KW - ADPKD

KW - chronic renal disease

KW - kidney volume

KW - polycystic kidney disease

KW - renal function

UR - http://www.scopus.com/inward/record.url?scp=84857789154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857789154&partnerID=8YFLogxK

U2 - 10.1038/ki.2011.411

DO - 10.1038/ki.2011.411

M3 - Article

VL - 81

SP - 577

EP - 585

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 6

ER -